Company profile for Ferrer Internacional

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Ferrer has joined the Barcelona City Council, EADA Business School and B Lab Spain in the Barcelona+B initiative, a pioneering project in Spain to promote social and business transformation and promote a more prosperous, sustainable and inclusive city. Given the need to act against the climate emergency and social inequalities, Barcelona+B is a pioneering initiative in Spain that seeks to improve the social and environmenta...
Ferrer has joined the Barcelona City Council, EADA Business School and B Lab Spain in the Barcelona+B initiative, a pioneering project in Spain to promote social and business transformation and promote a more prosperous, sustainable and inclusive city. Given the need to act against the climate emergency and social inequalities, Barcelona+B is a pioneering initiative in Spain that seeks to improve the social and environmental impact of companies and citizens, to turn them into the main agents of change and positive transformation.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Kaiserstraße, 100 D-52134, Herzogenrath (Alemania)
Telephone
Telephone
+4924075023110
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.ferrer.com/en/Ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-trial-in-progressive-supranuclear-palsy-psp-two-months-ahead-of-schedule

PRESS RELEASE
21 Oct 2025

https://www.businesswire.com/news/home/20251021806533/en/Ferrer-Completes-Recruitment-of-220-Patients-for-the-PROSPER-Study-a-Phase-II-Clinical-Trial-in-Progressive-Supranuclear-Palsy-PSP-Two-Months-Ahead-of-Schedule

BUSINESSWIRE
21 Oct 2025

https://www.businesswire.com/news/home/20251010035801/en/Prilenia-and-Ferrer-to-Share-New-Data-and-Analyses-of-Pridopidines-Impact-on-Huntingtons-Disease-at-the-Huntington-Study-Group-HSG-Congress

BUSINESSWIRE
10 Oct 2025

https://www.businesswire.com/news/home/20251006420172/en/Pridopidine-Pivotal-Phase-3-ALS-Study-Unveiled-at-NEALS-2025-Annual-Meeting

BUSINESSWIRE
06 Oct 2025

https://www.ferrer.com/en/Nature-Medicine-Publishes-Phase-3-Data-on-Pridopidine-in-Early-Stage-Huntingtons-Disease-Highlighting-Impact-on-Clinical-Progression

PRESS RELEASE
05 Sep 2025

https://www.businesswire.com/news/home/20250725635763/en/Prilenia-and-Ferrer-Provide-Update-on-European-Regulatory-Process-for-Pridopidine-in-Huntingtons-Disease

BUSINESSWIRE
25 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty